News

Pfizer Limited will hold a board meeting on November 3, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing. The company’s trading window for share transactions will remain closed for 48 hours after the financial results are made public, in accordance with SEBI regulations.

Pfizer Limited informed the BSE Limited and The National Stock Exchange of India Ltd. that KFin Technologies Limited, its Registrar & Share Transfer Agent, has confirmed compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.

Pfizer Limited informed the Bombay Stock Exchange and the National Stock Exchange of India that the trading window for dealing in shares of the company will be closed from September 30, 2026, until 48 hours after the unaudited financial results for the half year ending September 30, 2026, are made public.

Pfizer Limited announced that Mr. Sharad Goswami, Senior Director – Policy & Public Affairs, has resigned from the company effective September 25, 2026, to pursue opportunities outside Pfizer Limited, as disclosed to the Bombay Stock Exchange and the National Stock Exchange of India.

Pfizer Limited announced that it will discontinue the marketing, distribution, and sale of Minipress XL effective September 7, 2026, following a decision by Pfizer Inc. USA to discontinue the manufacture of the drug, and will receive a lump sum payment of USD 13.9 million, equivalent to Rs 131.38 crore, from Pfizer Inc. USA.